You are here

Article Text

Article menu
Download PDFPDF
Cervical Cancer
Sarcopenia Is an Important Prognostic Factor in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy
  1. Takanori Kiyotoki, MD,
  2. Keiichiro Nakamura, MD, PhD,
  3. Junko Haraga, MD,
  4. Chiaki Omichi, MD,
  5. Naoyuki Ida, MD,
  6. Masayuki Saijo, MD,
  7. Takeshi Nishida, MD,
  8. Tomoyuki Kusumoto, MD, PhD and
  9. Hisashi Masuyama, MD, PhD
  1. Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  1. Address correspondence and reprint requests to Keiichiro Nakamura, MD, PhD, Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-tyo, Kita-ku, Okayama 700-8558, Japan. E-mail: k-nakamu{at}cc.okayama-u.ac.jp.

Abstract

Objective This study aimed to investigate the correlation of sarcopenia findings with prognostic factors in patients with cervical cancer (CC) undergoing concurrent chemoradiotherapy (CCRT).

Methods We retrospectively collected data on body composition and clinicopathological features from the medical records of 60 patients with CC who underwent CCRT and analyzed correlations between prognosis and changes in body composition as measured by computed tomography (skeletal muscle and iliopsoas muscle [IM]). Statistical analyses were performed using the Mann-Whitney U test. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Cox proportional hazard regression was used for univariate and multivariate analyses.

Results The median follow-up for all patients who were alive at the last follow-up was 33.5 months (range, 1–104 months). The PFS and OS rates were worse for patients with at least 15.0% than for those with less than 15.0% loss of skeletal muscle and IM from baseline (P < 0.001 for both). Furthermore, multivariate analyses showed that at least 15.0% loss of IM was an independent prognostic factor for PFS and OS (P = 0.002 for both).

Conclusions Sarcopenia (≥15.0% loss of IM from baseline) was revealed to be an important prognostic factor in patients with CC undergoing CCRT.

  • Cervical cancer
  • Sarcopenia
  • Poor prognosis
  • Skeletal muscle
  • Iliopsoas muscle

https://doi.org/10.1097/IGC.0000000000001127

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • The authors declare no conflicts of interest.